標(biāo)題: Titlebook: Comparative Effectiveness Research in Health Services; Adrian Levy,Boris Sobolev Reference work 2016 Springer Science+Business Media New Y [打印本頁(yè)] 作者: 珍愛(ài) 時(shí)間: 2025-3-21 18:49
書目名稱Comparative Effectiveness Research in Health Services影響因子(影響力)
書目名稱Comparative Effectiveness Research in Health Services影響因子(影響力)學(xué)科排名
書目名稱Comparative Effectiveness Research in Health Services網(wǎng)絡(luò)公開度
書目名稱Comparative Effectiveness Research in Health Services網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Comparative Effectiveness Research in Health Services被引頻次
書目名稱Comparative Effectiveness Research in Health Services被引頻次學(xué)科排名
書目名稱Comparative Effectiveness Research in Health Services年度引用
書目名稱Comparative Effectiveness Research in Health Services年度引用學(xué)科排名
書目名稱Comparative Effectiveness Research in Health Services讀者反饋
書目名稱Comparative Effectiveness Research in Health Services讀者反饋學(xué)科排名
作者: Chromatic 時(shí)間: 2025-3-22 00:18 作者: 少量 時(shí)間: 2025-3-22 01:42
Comparative Effectiveness Research in Health Services978-1-4899-7600-0Series ISSN 2511-8293 Series E-ISSN 2511-8307 作者: expdient 時(shí)間: 2025-3-22 04:39
Adrian Levy,Boris SobolevCollates current thinking on how best to deliver health care from multiple disciplines.Familiarizes readers with core concepts & theories of health services, including data types.Presents a timely sum作者: avarice 時(shí)間: 2025-3-22 11:46 作者: 土坯 時(shí)間: 2025-3-22 16:50 作者: 土坯 時(shí)間: 2025-3-22 18:35 作者: 山崩 時(shí)間: 2025-3-22 22:06
https://doi.org/10.1007/978-3-658-29210-2s a means to control costs and improve patient care. The most important of these creates a new independent nonprofit entity known as the Patient-Centered Outcomes Research Institute (PCORI) with a mission to advance CER as a discipline. Related provisions in the ACA create new bodies to improve care作者: 無(wú)目標(biāo) 時(shí)間: 2025-3-23 02:14 作者: surmount 時(shí)間: 2025-3-23 08:23
https://doi.org/10.1007/978-3-658-29210-2sses can assist decision makers in making difficult choices. This chapter presents the application of a priority setting framework that has been used across countries across the full spectrum of health care and positions this framework as a vehicle for the application of comparative effectiveness re作者: Decline 時(shí)間: 2025-3-23 10:41
Fabian Kessl,Christian Reutlingern various settings for some time – most commonly as inputs to formal health technology assessment processes used to determine the medical, social, economic, and ethical issues related to the use of a health technology. As it is conceived in the United States, CER goes beyond health technology assess作者: Inflammation 時(shí)間: 2025-3-23 14:21
https://doi.org/10.1007/978-3-531-90330-9of evidence-based medicine. Effective dissemination of comparative effectiveness research findings to practicing clinicians can allow the health system to take advantage of this opportunity. This chapter reviews challenges in the current system of medical practice, licensing, and education that limi作者: mercenary 時(shí)間: 2025-3-23 20:13
https://doi.org/10.1007/978-3-531-92381-9ve assessments of medical technology consumer value. We discuss this claim in terms of prospect theory. We find that CER creates a different frame for making decisions about risk and gains that, in turn, changes perspectives on the expected returns and effective patent life of medical research and d作者: 摸索 時(shí)間: 2025-3-23 23:47
Fabian Kessl,Christian Reutlingers described by various terms such as evidence-based medicine, and health economics (mainly economic evaluation of healthcare interventions) were performed as part of the health technology assessment process..The majority of these activities were in the field of education and research development and作者: 浪費(fèi)物質(zhì) 時(shí)間: 2025-3-24 02:56 作者: bile648 時(shí)間: 2025-3-24 09:45 作者: ATOPY 時(shí)間: 2025-3-24 11:43
https://doi.org/10.1007/978-3-658-32799-6arch for the highest quality of care in the health system. The specific question addressed is: can the goals of CER (i.e., evidence-informed decision-making to improve health-care quality) be achieved for all potential users of CER information (i.e., patients, clinicians, purchasers, and policy-make作者: 消散 時(shí)間: 2025-3-24 16:34 作者: Mercantile 時(shí)間: 2025-3-24 22:14 作者: 思考而得 時(shí)間: 2025-3-25 00:16 作者: 大量殺死 時(shí)間: 2025-3-25 03:27 作者: 秘傳 時(shí)間: 2025-3-25 08:41
Inken Carstensen-Egwuom,Birte Schr?derechnology decision-making, without hindering access to needed and effective treatments. A number of policy mechanisms to deal with this issue are available, with different methods of execution. These mechanisms have been purported to improve and hasten the reimbursement process of promising health t作者: 好色 時(shí)間: 2025-3-25 15:28 作者: compassion 時(shí)間: 2025-3-25 17:47
Andreas Müller,Anna-Lisa Mülleratistical methods for combining results when conducting comparative effectiveness research (CER). This chapter provides a brief overview of the recent statistical advances for combining results and the rationale behind the development of novel statistical methods. We broadly categorize statistical a作者: TAP 時(shí)間: 2025-3-25 21:45 作者: Outmoded 時(shí)間: 2025-3-26 01:52 作者: 血統(tǒng) 時(shí)間: 2025-3-26 06:06 作者: Occupation 時(shí)間: 2025-3-26 11:19 作者: 巡回 時(shí)間: 2025-3-26 14:35 作者: 食物 時(shí)間: 2025-3-26 20:34 作者: verdict 時(shí)間: 2025-3-26 22:31 作者: integrated 時(shí)間: 2025-3-27 02:39
Reference work 2016rn from the general public, governments in virtually all countries with developed and rapidly developing economies have been actively seeking and promoting ways of improving the patient experience of health care, improving the health of populations, and reducing the per capita cost of health care. W作者: ALIBI 時(shí)間: 2025-3-27 07:29 作者: 戲法 時(shí)間: 2025-3-27 12:15 作者: vertebrate 時(shí)間: 2025-3-27 14:17 作者: 出血 時(shí)間: 2025-3-27 19:29
Neustrukturierung des Sozialraums Europa,ment’s failure through reliance on randomized controlled trials measuring efficacy and not the real-world effectiveness of treatment options. Several recent initiatives energizing the need for comparative effectiveness research have also aligned with the recognized need for patient participation in all aspects of healthcare research and practice.作者: 模仿 時(shí)間: 2025-3-27 22:48 作者: engender 時(shí)間: 2025-3-28 02:48
National Approaches to Comparative Effectiveness Research,cross various European countries in addition to Australia and Canada. Adopting an emerging United States-centric definition of CER, which focuses on clinical evidence, this chapter outlines the similarities and differences across settings in terms of how CER evidence is generated and synthesized and how it contributes to decision-making.作者: 取回 時(shí)間: 2025-3-28 07:45 作者: watertight, 時(shí)間: 2025-3-28 12:12 作者: buoyant 時(shí)間: 2025-3-28 14:40 作者: Transfusion 時(shí)間: 2025-3-28 19:43 作者: 消音器 時(shí)間: 2025-3-28 23:05 作者: 恃強(qiáng)凌弱 時(shí)間: 2025-3-29 04:34
https://doi.org/10.1007/978-3-658-29210-2rom political disputes that preceded the ACA’s passage and that continue even after its implementation. For PCORI to succeed, it will have to remain attentive to aspects of the broader policy and political context in which CER is conducted. If it effectively does so, it can establish CER as an impor作者: 浮夸 時(shí)間: 2025-3-29 09:28 作者: Communicate 時(shí)間: 2025-3-29 12:35 作者: FOLLY 時(shí)間: 2025-3-29 16:15
Fabian Kessl,Christian Reutlingerribes the institutionalization of those initiatives in the Ministry of Health. This chapter also discusses the challenges in building human resources capacity and developing an infrastructure to conduct CER..CER can be a powerful initiative to inform healthcare decision-making. Incorporating communi作者: 機(jī)制 時(shí)間: 2025-3-29 22:45
Neustrukturierung des Sozialraums Europa,volved as a multidisciplinary science, drawing principles from the behavioral and social sciences, process engineering, economics, and traditional health services research. Parallel to this evolution, new methodologies and evaluation approaches have emerged to track the processes, organizational con作者: 爭(zhēng)論 時(shí)間: 2025-3-29 23:59 作者: debase 時(shí)間: 2025-3-30 07:32 作者: FUME 時(shí)間: 2025-3-30 09:45
https://doi.org/10.1007/978-3-658-29799-2al for improving decision-making at all levels. In practice, this notion of generating individualized information and using it to deliver care is denoted as personalized medicine (PM), which allows for the possibility of variation in medical quality based on demographics, comorbidities, preferences,作者: 直言不諱 時(shí)間: 2025-3-30 12:51
https://doi.org/10.1007/978-3-662-56277-2plicit consideration by the health technology assessment community of the potential differences between medical devices and drugs either in their assessment or appraisal processes. Comparing medical devices to drugs highlights the challenges in the common assessment – both comparative effectiveness 作者: Emasculate 時(shí)間: 2025-3-30 19:03
Inken Carstensen-Egwuom,Birte Schr?derdditional evidence to support the “real-world” value of promising health technologies as a condition for provisional coverage. As such, it represents a middle ground between the conventional “yes” or “no” reimbursement decisions, giving the opportunity to satisfy all parties (decision-makers, pharma作者: 貧窮地活 時(shí)間: 2025-3-30 23:21
Andreas Müller,Anna-Lisa Müllersly, statistical methods for combining patient-reported outcomes, statistical methods for combining data for multiple parameters using comprehensive health economic decision modeling, statistical methods for combining data in benefit-harm assessments, and statistical methods for combining data over 作者: 打包 時(shí)間: 2025-3-31 02:45
2511-8293 ted outcomes. ?.Comparative Effectiveness Research.?presents a series of chapters of relevance including introductions to areas that are being incorporated when comparing treatments, country-specific applicatio978-1-4899-7600-0Series ISSN 2511-8293 Series E-ISSN 2511-8307 作者: Temporal-Lobe 時(shí)間: 2025-3-31 08:44
Comparative Effectiveness Research and Health Reform in the USA,rom political disputes that preceded the ACA’s passage and that continue even after its implementation. For PCORI to succeed, it will have to remain attentive to aspects of the broader policy and political context in which CER is conducted. If it effectively does so, it can establish CER as an impor作者: 連系 時(shí)間: 2025-3-31 09:41
Comparative Effectiveness Research in Health Technology Assessment,issues presented by various research designs, including clinical trials, observational studies, systematic review, and meta-analysis, the advent of engagement practices, the emergent themes of patient-centeredness and personalization, and the problem of assessing the clinical and economic value of h作者: 沉默 時(shí)間: 2025-3-31 14:09
Comparative Effectiveness Research and Priority Setting,oject scope. While success can never be guaranteed, these lessons should be useful to those charged with allocating available resources as well as those who may be called upon to support such activity. The chapter closes with discussion of future areas for development in this field along with a numb作者: transient-pain 時(shí)間: 2025-3-31 17:33 作者: Defense 時(shí)間: 2025-3-31 21:59 作者: reserve 時(shí)間: 2025-4-1 04:47
Costs in Comparative Effectiveness Research,f costs. This is true for all potential users of CER information although the perspective of cost information required by each stakeholder group, not surprisingly, varies. Therefore, the contention is that CER, when coupled with information about cost, provides useful direction in creating high-qual作者: 新手 時(shí)間: 2025-4-1 07:12
Traditional and Innovative Study Designs in Comparative Effectiveness Research, very novel approaches involving simulation to capitalize on available trial data but incorporating information from observational studies to better estimate the comparative effects. These designs are presented in this chapter.作者: Foam-Cells 時(shí)間: 2025-4-1 11:08 作者: LINE 時(shí)間: 2025-4-1 18:21
Comparing Drug and Nondrug Technologies in Comparative Effectiveness Research,plicit consideration by the health technology assessment community of the potential differences between medical devices and drugs either in their assessment or appraisal processes. Comparing medical devices to drugs highlights the challenges in the common assessment – both comparative effectiveness 作者: Fabric 時(shí)間: 2025-4-1 22:14
Coverage with Evidence Development in Comparative Effectiveness Research,dditional evidence to support the “real-world” value of promising health technologies as a condition for provisional coverage. As such, it represents a middle ground between the conventional “yes” or “no” reimbursement decisions, giving the opportunity to satisfy all parties (decision-makers, pharma作者: 材料等 時(shí)間: 2025-4-1 23:01
